Toxicological aspects of a novel 9-aminoanthracycline, SM-5887

Japanese Journal of Cancer Research : Gann
S MorisadaM Fukui

Abstract

The toxicological characteristics of SM-5887 were evaluated in mice after a bolus intravenous injection, and compared with those of adriamycin (ADR). The acute toxic signs observed after SM-5887 administration were body weight decrease, ataxia, hair loss, and myelosuppression. They were qualitatively comparable to those induced by ADR. The 50% lethal dose values determined by 14-day observation after drug administration were in the range of 32 to 50 mg/kg for SM-5887 and 16 to more than 20 mg/kg for ADR in four strains of mice. The maximum tolerated doses (MTD) were estimated to be 25 mg/kg for SM-5887 and 12.5 mg/kg for ADR (no death or body weight loss of more than 3 g occurred). When 14-day survivors were further observed until 90 days after drug administration, ADR frequently and dose-independently showed delayed-type lethal toxicity at doses of more than 10 mg/kg, whereas SM-5887 did not. The myelosuppression of SM-5887 was more severe even at a half of the MTD than that of ADR at the MTD, but its recovery was more rapid than that after ADR. In addition, when the drugs were injected into the subplantar region of mouse hind paws, ADR induced a severe inflammatory reaction, whereas SM-5887 yielded only a slight one. The data...Continue Reading

References

Sep 1, 1976·Cancer·R RudolphR A Pattillo
Jan 1, 1981·Cancer Chemotherapy and Pharmacology·T H CorbettF M Schabel

❮ Previous
Next ❯

Citations

Jul 19, 2014·Cancer Chemotherapy and Pharmacology·Takaya IkedaUNKNOWN Nagasaki Thoracic Oncology Group
May 1, 2009·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Minoru FukudaUNKNOWN Nagasaki Thoracic Oncology Group
Mar 5, 2008·Mayo Clinic Proceedings·Taimur SherAlex A Adjei
Jun 29, 2010·Cancer Treatment Reviews·Young Hak Kim, Michiaki Mishima
Aug 2, 2003·Nihon yakurigaku zasshi. Folia pharmacologica Japonica·Mitsuharu HanadaTakao Murayama
Dec 10, 2003·Cancer Science·Naoshi ObaraToshiro Nagasawa
Apr 29, 2021·Angewandte Chemie·Lorena Simón-GraciaTambet Teesalu

❮ Previous
Next ❯

Related Concepts

Related Feeds

Ataxias

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on different types of ataxias here.

Anti-inflammatory Treatments

A drug or substance that reduces inflammation (redness, swelling, and pain) in the body. Anti-inflammatory agents block certain substances in the body that cause inflammation and swelling. Discover the latest research on anti-inflammatory treatments here

Ataxia

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.

Ataxias (MDS)

Ataxia is a neurological condition characterized by lack of voluntary coordination of muscle movements including loss of coordination, balance, and speech. Discover the latest research on ataxia here.